A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Official title

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

Overview

The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement. All study medicines are given in cycles that last 28 days. Everyone taking part in this study will receive elranatamab as a shot under the skin. Iberdomide will be taken by mouth once a day for 21 days over a 28-day cycle. Participants will receive study medicine until: * their disease progresses or, * they experience unacceptable side effects or, * they choose to no longer take part in the study. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and can be used for multiple myeloma treatment.

Interventions

• Drug Elranatamab
  BCMA-CD3 bispecific antibody
• Drug Iberdomide
  cereblon-modulating agent

Primary outcome measures

• Part 1: Number of participants with dose limiting toxicity (DLT) [Time frame: Cycle 1, about 28 days]
• Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment [Time frame: Assessed from baseline up to 90 days after last dose of study treatment]

Secondary outcome measures (12)

• Part 1: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment [Time frame: Assessed from baseline up to 90 days after last dose of study treatment]
• Part 1 and Part 2: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity [Time frame: Assessed from baseline up to 90 days after last dose of study treatment]
• Part 1 and Part 2: Number of Participants with Clinically Significant Change from Baseline in Laboratory Abnormalities [Time frame: Assessed from baseline up to 90 days after last dose of study treatment]
• Part 1 and Part 2: Percentage of Participants with Objective Response Rate (ORR) [Time frame: Assessed for approximately 2 years]
• Part 1 and Part 2: Percentage of Participants with Complete Response Rate (CRR) [Time frame: Assessed for approximately 2 years]
• Part 1 and Part 2: Time to Response (TTR) [Time frame: Assessed for approximately 2 years]
• Part 1 and Part 2: Duration of Response (DOR) [Time frame: Assessed for approximately 2 years]
• Part 1 and Part 2: Duration of Complete Response (DOCR) [Time frame: Assessed for approximately 2 years]
• Part 1 and Part 2: Time of Progression Free Survival (PFS) [Time frame: Assessed for approximately 2 years]
• Part 1 and Part 2: Time of Overall Survival (OS) [Time frame: Assessed for approximately 2 years]
• Part 1 and Part 2: Minimal Residual Disease (MRD) Negativity Rate [Time frame: Assessed for approximately 2 years]
• Part 1 and Part 2: Concentrations of elranatamab [Time frame: Assessed for approximately 2 years]

Eligibility criteria

Inclusion criteria

• Prior diagnosis of multiple myeloma as defined by IMWG criteria
• Measurable disease based on IMWG criteria as defined by at least 1 of the following:
• Serum M-protein ≥0.5 g/dL by SPEP
• Urinary M-protein excretion ≥200 mg/24 hour by UPEP
• Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FL ratio (<0.26 or >1.65)
• Part 1: Received 2-4 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor.
• Part 2: Received 1-3 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor.
• ECOG performance status 0-1
• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1

Exclusion criteria

• Plasma cell leukemia, Smoldering multiple myeloma, Waldenström's macroglobulinemia, Amyloidosis, POEMS Syndrome
• Impaired cardiovascular function or clinically significant cardiovascular diseases
• Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease
• Participants with any active, uncontrolled bacterial, fungal, or viral infection
• Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
• Previous treatment with:
• BCMA-directed or CD3 redirecting therapy
• Iberdomide (CC-220) or Mezigdomide
• Administration of strong inhibitor or inducer of CYP3A4/5 within 2 weeks prior to dosing and during the study
• Administration with an investigational product within 30 days preceding the first dose of study intervention
• Participant is unable or unwilling to undergo protocol required thromboembolism prophylaxis

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 34 centers

• Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables
• University of Miami Hospital and Clinics Deerfield Beach — Deerfield Beach
• Sylvester Comprehensive Cancer Center- Doral — Doral
• Sylvester Comprehensive Cancer Center — Miami
• University of Miami Hospital and Clinics — Miami
• Sylvester Comprehensive Cancer Center Kendall — Miami
• Sylvester Comprehensive Cancer Center Plantation — Plantation
• Emory University Hospital Midtown — Atlanta
• … and 26 more centers

Australia · 6 centers

• Liverpool Hospital — Liverpool
• Calvary Mater Newcastle — Waratah
• Townsville University Hospital — Douglas
• Epworth Freemasons — East Melbourne
• Epworth Hospital — Richmond
• Slade Pharmacy — Richmond

Canada · 3 centers

• Dr. Everett Chalmers Regional Hospital — Fredericton
• CIUSSS de l'Est-de-l'Île-de-Montréal — Montreal
• Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospital — Sherbrooke

Identifiers

NCT: NCT06215118 · C1071030 · MagnetisMM-30

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗